Model Number 3CX*FX15RW40C |
Device Problem
Unable to Obtain Readings (1516)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 12/12/2019 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the temperature port did not work.No known impact or consequence to patient.The product was not changed out.The surgery was completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date); g4 (date received by manufacturer); g7 (indication that this is a follow-up report); h2 (follow-up due to additional information and device evaluation); h3 (device evaluated by manufacturer); h4 (device manufacture date); h6 (identification of evaluation codes 10, 11, 3331, 4203, 4307).Method code #1: 10 - actual device evaluated.Method code #2: 11 - 11 - testing of device from same lot/batch retained by manufacturer.Method code #3: 3331 - analysis of production records.Results code: 114 - operational problem identified.Conclusions code: 4307 - cause traced to component failure the affected sample was inspected upon receipt and confirmed to have a non-functioning arterial thermistor.Representative retention samples from a variety of product/lot number combinations were tested and found to be functioning properly.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on jan 2, 2020.A second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|